Company Profile

Wintac Limited is an India-based company, which is engaged in the formulations business. The Company is involved in formulation sales, manufacturing charges and formulation development. Its products are classified under categories, including injectable and ophthalmic. Its ophthalmic product range includes Timolol Maleate Eye Drops, Atropine Eye Drops, Fluorometholone Eye Drops, Olopatadine Eye Drops, Chloramphenicol Eye Drops, Diclofenac Eye Drops, Ketorolac Tromethamine Eye Drops and Bromfenac Eye Drops. Its injectable product range includes Diclofenac Injection, Pheniramine Maleate Injection, Iron Sucrose Injection, Pentoxifylline Injection, Atropine Injection, Hyoscine Butyl Bromide Injection, Ondansetron Injection, Metoclopramide Injection, Tramadol Injection, Analgin Injection, Gentamicin Sulphate Injection and Levofloxacin Injection. The Company carries out formulation development activities in the export market, including the United States, Canada, Australia and Europe.

Employees

Sector

Pharmaceuticals

More about the company

10/23/10	Somerset Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2023	CI
11/22/11	Wintac Limited Reports Earnings Results for the Full Year Ended March 31, 2022	CI
12/20/12	Wintac Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	CI
07/20/07	Wintac Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	CI
22/20/22	Wintac Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	CI
04/20/04	Wintac Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019	CI
04/20/04	Wintac Limited Appoints S. Nanthitha as Additional Director	CI
27/20/27	Wintac Limited Announces Resignation of Ms. K. M. Ganga as Independent Director	CI
13/19/13	Wintac Limited Reports Earnings Results for the Second Quarter Ended September 30, 2019	CI
12/19/12	Wintac Limited Reports Earnings Results for the First Quarter Ended June 30, 2019	CI
23/19/23	Wintac Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019	CI
27/19/27	Par Formulations Pvt Ltd cancelled the acquisition of Pharmaceutical Business from Wintac Limited.	CI
11/19/11	Wintac Ltd. Reports Earnings Results for the Third Quarter Ended December 31, 2018	CI

Manager	Title	Age	Since
Sudhakar Varamballi Krupendra DFI	Director of Finance/CFO	-	01/02/2015
Velusamy Jaiashokan COO	Chief Operating Officer	-	01/01/2022
Karupannan Poongudi Murali PRN	Corporate Officer/Principal	-	01/01/2021

Director	Title	Age	Since
R. A. Thirumoorti BRD	Director/Board Member	53	11/07/2013
K. Paranjothy CHM	Chairman	79	-
Karupannan Poongudi Murali BRD	Director/Board Member	-	01/01/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WINTAC LIMITED	+0.31%	+0.47%	-	-	4.66Cr
ELI LILLY AND COMPANY	+2.68%	+2.56%	+59.32%	+114.68%	1,02600Cr
JOHNSON & JOHNSON	+0.56%	+0.17%	+53.19%	+68.65%	65TCr
ABBVIE INC.	+0.02%	+0.42%	+20.51%	+73.58%	47TCr
ROCHE HOLDING AG	+0.06%	+0.61%	+39.82%	+45.71%	35TCr
NOVARTIS AG	+1.16%	+2.53%	+21.60%	+29.39%	27TCr
ASTRAZENECA PLC	-0.24%	-0.23%	+10.62%	+12.26%	26TCr
AMGEN INC.	-0.01%	+6.91%	+45.42%	+51.68%	22TCr
GILEAD SCIENCES, INC.	-1.11%	-0.80%	+31.69%	+99.56%	19TCr
NOVO NORDISK A/S	+0.30%	-9.43%	-31.91%	-60.56%	17TCr
Average	+0.10%	+0.52%	+27.81%	+48.33%	39.99TCr
Weighted average by Cap.	+0.12%	+1.06%	+38.36%	+67.68%

Wintac Limited Share Price

Stocks

524758

INE812C01016

Pharmaceuticals

Latest news: Wintac Limited

Press Releases: Wintac Limited

Quotes and Performance

Managers and Directors: Wintac Limited

Other Pharmaceuticals

Company Profile